Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Artelo Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Artelo Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Matsui Connie | Director | – | Jul 21, 2026 | 3 |
| Blayney Douglas | Director | – | Jul 21, 2026 | 2 |
| Reyes Gregory | Director | – | Jul 21, 2026 | 2 |
| Emanuele Robert Martin | Director | – | Jul 21, 2026 | 2 |
| Kelly Steven | Director | – | Jul 21, 2026 | 2 |
| Seymour Tamara A | Director | – | Jul 21, 2026 | 3 |
| Gorgas Gregory D. | Pres, CEO, CFO, Treas & Secr | 2,400Indirect | Feb 2, 2026 | 2 |
| Spring Mark Edward | Chief Financial Officer | – | Feb 2, 2026 | 1 |
| Beck John W | Director | – | Jul 26, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2025 (view filing) | May 1 | 4 days | Seymour Tamara ADirector | PPurchaseConvertible Promissory Note | – | – | – | – | DerivativePrice outlier |
| May 5, 2025 (view filing) | May 1 | 4 days | Matsui ConnieDirector | PPurchaseConvertible Promissory Note | – | – | – | – | DerivativePrice outlier |
| May 5, 2025 (view filing) | May 1 | 4 days | Gorgas Gregory D.Pres, CEO, CFO, Treas & Secr | PPurchaseConvertible Promissory Note | – | – | – | – | DerivativePrice outlier |
| Aug 12, 2022 (view filing) | Aug 12 | Same day | Gorgas Gregory D.Pres, CEO, CFO, Treas & Secr | PPurchase | +1.20K | $4.00 | +$4.80K | +100.0%2.40K after | |
| Aug 11, 2022 (view filing) | Aug 11 | Same day | Gorgas Gregory D.Pres, CEO, CFO, Treas & Secr | PPurchase | +1.20K | $4.03 | +$4.84K | New position1.20K after |